MiR-630 suppresses breast cancer progression by targeting metadherin

Oncotarget

Volumn 7, Issue 2, 2016, Pages 1288-1299

  Zhou, Ci Xiang ^a   Wang, Chen Long ^a   Yu, An Lu ^a   Wang, Qiu Yu ^a   Zhan, Meng Na ^a   Tang, Jun ^b   Gong, Xiu Feng ^a   Yin, Qian Qian ^a   He, Ming ^a   He, Jian Rong ^c   Chen, Guo Qiang ^a,b   Zhao, Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Chinese Academy of Sciences   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Metastasis; MiR 630; MTDH

Indexed keywords

BETA CATENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 630; PROTEIN KINASE B; UNCLASSIFIED DRUG; WNT PROTEIN; CELL ADHESION MOLECULE; MIRN630 MICRORNA, HUMAN; MTDH PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BT549 CELL LINE; CANCER GROWTH; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ECTOPIC EXPRESSION; FEMALE; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LUNG METASTASIS; MDA MB 231 LUC CELL LINE; MOUSE; MTDH GENE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR INVASION; VIRAL GENE DELIVERY SYSTEM; ADULT; AGED; ANIMAL; BREAST TUMOR; CELL LINE; CELL MOTION; DISEASE COURSE; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; NONOBESE DIABETIC MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VERY ELDERLY; WESTERN BLOTTING; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, INBRED NOD; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84957650982     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6339     Document Type: Article

References (41)

1. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608:1-22.
2. Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer. 2008; 8:224-233.
3. Gupta GP and Massague J. Cancer metastasis: building a framework. Cell. 2006; 127:679-695.
4. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12:895-904.
5. Vanharanta S and Massague J. Origins of metastatic traits. Cancer Cell. 2013; 24:410-421.
6. Berx G and van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009; 1:a003129.
7. Cavallaro U and Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004; 4:118-132.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
9. Alvarez-Garcia I and Miska EA. MicroRNA functions in animal development and human disease. Development. 2005; 132:4653-4662.
10. Inui M, Martello G and Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 11:252-263.
11. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:2999-3004.
12. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857-866.
13. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL and Weinberg RA. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009; 137:1032-1046.
14. Ryu S, McDonnell K, Choi H, Gao D, Hahn M, Joshi N, Park SM, Catena R, Do Y, Brazin J, Vahdat LT, Silver RB and Mittal V. Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell. 2013; 23:63-76.
15. Krichevsky AM and Gabriely G. miR-21: a small multifaceted RNA. J Cell Mol Med. 2009; 13:39-53.
16. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E and Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008; 10:202-210.
17. Park SM, Gaur AB, Lengyel E and Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008; 22:894-907.
18. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10:593-601.
19. Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, Cao DX, Chen GQ, He JR and Zhao Q. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 2013; 34:713-722.
20. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ and Fisher PB. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene. 2005; 353:8-15.
21. Tokunaga E, Nakashima Y, Yamashita N, Hisamatsu Y, Okada S, Akiyoshi S, Aishima S, Kitao H, Morita M and Maehara Y. Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer. 2014; 21:341-349.
22. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG and Kang Y. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009; 15:9-20.
23. Brown DM and Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell. 2004; 5:365-374.
24. Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D and Fisher PB. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:21300-21305.
25. Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ and Zhao Q. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011; 32:2-9.
26. Valastyan S and Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147:275-292.
27. Benton G, Kleinman HK, George J and Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer. 2011; 128:1751-1757.
28. Kleinman HK and Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005; 15:378-386.
29. Friedman RC, Farh KK, Burge CB and Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome research. 2009; 19:92-105.
30. Kikuchi A and Monga SP. PDGFRalpha in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer. Gene expression. 2015; 16:109-127.
31. Shen X, Li CC, Aponte AM, Shen RF, Billings EM, Moss J and Vaughan M. Brefeldin A-inhibited ADP-ribosylation factor activator BIG2 regulates cell migration via integrin beta1 cycling and actin remodeling. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:14464-14469.
32. Emdad L, Das SK, Dasgupta S, Hu B, Sarkar D and Fisher PB. AEG-1/MTDH/LYRIC: signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis. Adv Cancer Res. 2013; 120:75-111.
33. Sobral LM, Sousa LO, Coletta RD, Cabral H, Greene LJ, Tajara EH, Gutkind JS, Curti C and Leopoldino AM. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. Molecular cancer. 2014; 13:32.
34. Fantozzi A and Christofori G. Mouse models of breast cancer metastasis. Breast Cancer Res. 2006; 8:212.
35. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
36. Zhao JJ, Chen PJ, Duan RQ, Li KJ, Wang YZ and Li Y. Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. International journal of clinical and experimental pathology. 2014; 7:3318-3323.
37. Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J and O'Driscoll L. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Molecular cancer. 2014; 13:71.
38. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupe P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E and Kroemer G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer research. 2010; 70:1793-1803.
39. Zhang JW, Li Y, Zeng XC, Zhang T, Fu BS, Yi HM, Zhang Q and Jiang N. miR-630 overexpression in hepatocellular carcinoma tissues is positively correlated with alpha-fetoprotein. Medical science monitor: international medical journal of experimental and clinical research. 2015; 21:667-673.
40. Kuo TC, Tan CT, Chang YW, Hong CC, Lee WJ, Chen MW, Jeng YM, Chiou J, Yu P, Chen PS, Wang MY, Hsiao M, Su JL and Kuo ML. Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. The Journal of clinical investigation. 2013; 123:1082-1095.
41. Wan L, Lu X, Yuan S, Wei Y, Guo F, Shen M, Yuan M, Chakrabarti R, Hua Y, Smith HA, Blanco MA, Chekmareva M, Wu H, Bronson RT, Haffty BG, Xing Y, et al. MTDHSND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene-and carcinogeninduced mammary tumors. Cancer Cell. 2014; 26:92-105.